These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 38918871)

  • 21. Phagocyte-specific S100 proteins and high-sensitivity C reactive protein as biomarkers for a risk-adapted treatment to maintain remission in juvenile idiopathic arthritis: a comparative study.
    Gerss J; Roth J; Holzinger D; Ruperto N; Wittkowski H; Frosch M; Wulffraat N; Wedderburn L; Stanevicha V; Mihaylova D; Harjacek M; Len C; Toppino C; Masi M; Minden K; Saurenmann T; Uziel Y; Vesely R; Apaz MT; Kuester RM; Elorduy MJ; Burgos-Vargas R; Ioseliani M; Magni-Manzoni S; Unsal E; Anton J; Balogh Z; Hagelberg S; Mazur-Zielinska H; Tauber T; Martini A; Foell D;
    Ann Rheum Dis; 2012 Dec; 71(12):1991-7. PubMed ID: 22689317
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk Factors and Biomarkers for the Occurrence of Uveitis in Juvenile Idiopathic Arthritis: Data From the Inception Cohort of Newly Diagnosed Patients With Juvenile Idiopathic Arthritis Study.
    Tappeiner C; Klotsche J; Sengler C; Niewerth M; Liedmann I; Walscheid K; Lavric M; Foell D; Minden K; Heiligenhaus A
    Arthritis Rheumatol; 2018 Oct; 70(10):1685-1694. PubMed ID: 29732713
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial.
    Foeldvari I; Constantin T; Vojinović J; Horneff G; Chasnyk V; Dehoorne J; Panaviene V; Sušić G; Stanevicha V; Kobusinska K; Zuber Z; Dobrzyniecka B; Nikishina I; Bader-Meunier B; Breda L; Doležalová P; Job-Deslandre C; Rumba-Rozenfelde I; Wulffraat N; Pedersen RD; Bukowski JF; Vlahos B; Martini A; Ruperto N;
    Arthritis Res Ther; 2019 May; 21(1):125. PubMed ID: 31122296
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum S100A12 and temporomandibular joint magnetic resonance imaging in juvenile idiopathic arthritis Egyptian patients: a case control study.
    Abdul-Aziez OA; Saber NZ; El-Bakry SA; Mohammad AA; Abdel-Maksud SS; Ali Y
    Pak J Biol Sci; 2010 Feb; 13(3):101-13. PubMed ID: 20437698
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biomarker Changes in Response to Tofacitinib Treatment in Patients with Polyarticular Course Juvenile Idiopathic Arthritis.
    Ogbu EA; Brunner HI; Eloseily E; Butbul Aviel Y; Nanda K; Schmeling H; Tory H; Uziel Y; Viola DO; Wahezi DM; Tarvin SE; Sproles A; Chen C; Ruperto N; Huang B; Grom A; Thornton S;
    Arthritis Care Res (Hoboken); 2024 Aug; ():. PubMed ID: 39135452
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical Juvenile Arthritis Disease Activity Score proves to be a useful tool in treat-to-target therapy in juvenile idiopathic arthritis.
    Swart JF; van Dijkhuizen EHP; Wulffraat NM; de Roock S
    Ann Rheum Dis; 2018 Mar; 77(3):336-342. PubMed ID: 29138257
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Decreases in serum levels of S100A8/9 (calprotectin) correlate with improvements in total swollen joint count in patients with recent-onset rheumatoid arthritis.
    Andrés Cerezo L; Mann H; Pecha O; Pleštilová L; Pavelka K; Vencovský J; Senolt L
    Arthritis Res Ther; 2011 Jul; 13(4):R122. PubMed ID: 21791097
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimizing the Start Time of Biologics in Polyarticular Juvenile Idiopathic Arthritis: A Comparative Effectiveness Study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans.
    Kimura Y; Schanberg LE; Tomlinson GA; Riordan ME; Dennos AC; Del Gaizo V; Murphy KL; Weiss PF; Natter MD; Feldman BM; Ringold S;
    Arthritis Rheumatol; 2021 Oct; 73(10):1898-1909. PubMed ID: 34105312
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Granulocyte-Specific Protein S100A12 as a Potential Prognostic Factor Affecting Aggressiveness of Therapy in Patients with Juvenile Idiopathic Arthritis.
    Orczyk K; Smolewska E
    J Immunol Res; 2018; 2018():5349837. PubMed ID: 30426025
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term safety, efficacy, and quality of life in patients with juvenile idiopathic arthritis treated with intravenous abatacept for up to seven years.
    Lovell DJ; Ruperto N; Mouy R; Paz E; Rubio-Pérez N; Silva CA; Abud-Mendoza C; Burgos-Vargas R; Gerloni V; Melo-Gomes JA; Saad-Magalhaes C; Chavez-Corrales J; Huemer C; Kivitz A; Blanco FJ; Foeldvari I; Hofer M; Huppertz HI; Job Deslandre C; Minden K; Punaro M; Block AJ; Giannini EH; Martini A;
    Arthritis Rheumatol; 2015 Oct; 67(10):2759-70. PubMed ID: 26097215
    [TBL] [Abstract][Full Text] [Related]  

  • 31. S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin.
    Wittkowski H; Frosch M; Wulffraat N; Goldbach-Mansky R; Kallinich T; Kuemmerle-Deschner J; Frühwald MC; Dassmann S; Pham TH; Roth J; Foell D
    Arthritis Rheum; 2008 Dec; 58(12):3924-31. PubMed ID: 19035478
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tocilizumab for juvenile idiopathic arthritis: a single-center case series.
    Yazılıtaş F; Özdel S; Şimşek D; Aydoğ Ö; Çakıcı EK; Can GG; Güngör T; Bülbül M
    Sao Paulo Med J; 2019; 137(6):517-522. PubMed ID: 32159638
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improved Disease Course Associated With Early Initiation of Biologics in Polyarticular Juvenile Idiopathic Arthritis: Trajectory Analysis of a Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans Study.
    Ong MS; Ringold S; Kimura Y; Schanberg LE; Tomlinson GA; Natter MD;
    Arthritis Rheumatol; 2021 Oct; 73(10):1910-1920. PubMed ID: 34105303
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and Safety of Tocilizumab for Polyarticular-Course Juvenile Idiopathic Arthritis in the Open-Label Two-Year Extension of a Phase III Trial.
    Brunner HI; Ruperto N; Zuber Z; Cuttica R; Keltsev V; Xavier RM; Burgos-Vargas R; Penades IC; Silverman ED; Espada G; Zavaler MF; Kimura Y; Duarte C; Job-Deslandre C; Joos R; Douglass W; Wimalasundera S; Bharucha KN; Wells C; Lovell DJ; Martini A; de Benedetti F;
    Arthritis Rheumatol; 2021 Mar; 73(3):530-541. PubMed ID: 32951358
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Urine and serum S100A8/A9 and S100A12 associate with active lupus nephritis and may predict response to rituximab treatment.
    Davies JC; Midgley A; Carlsson E; Donohue S; Bruce IN; Beresford MW; Hedrich CM
    RMD Open; 2020 Jul; 6(2):. PubMed ID: 32723832
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial.
    Brunner HI; Ruperto N; Zuber Z; Keane C; Harari O; Kenwright A; Lu P; Cuttica R; Keltsev V; Xavier RM; Calvo I; Nikishina I; Rubio-Pérez N; Alexeeva E; Chasnyk V; Horneff G; Opoka-Winiarska V; Quartier P; Silva CA; Silverman E; Spindler A; Baildam E; Gámir ML; Martin A; Rietschel C; Siri D; Smolewska E; Lovell D; Martini A; De Benedetti F; ;
    Ann Rheum Dis; 2015 Jun; 74(6):1110-7. PubMed ID: 24834925
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevention of disease flares by risk-adapted stratification of therapy withdrawal in juvenile idiopathic arthritis: results from the PREVENT-JIA trial.
    Gerss J; Tedy M; Klein A; Horneff G; Miranda-Garcia M; Kessel C; Holzinger D; Stanevica V; Swart JF; Cabral DA; Brunner HI; Foell D
    Ann Rheum Dis; 2022 Jul; 81(7):990-997. PubMed ID: 35260388
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial.
    Ruperto N; Lovell DJ; Quartier P; Paz E; Rubio-Pérez N; Silva CA; Abud-Mendoza C; Burgos-Vargas R; Gerloni V; Melo-Gomes JA; Saad-Magalhães C; Sztajnbok F; Goldenstein-Schainberg C; Scheinberg M; Penades IC; Fischbach M; Orozco J; Hashkes PJ; Hom C; Jung L; Lepore L; Oliveira S; Wallace CA; Sigal LH; Block AJ; Covucci A; Martini A; Giannini EH; ;
    Lancet; 2008 Aug; 372(9636):383-91. PubMed ID: 18632147
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MRP8/14 and neutrophil elastase for predicting treatment response and occurrence of flare in patients with juvenile idiopathic arthritis.
    Barendregt AM; Veldkamp SR; Hissink Muller PCE; van de Geer A; Aarts C; van Gulik EC; Schilham MW; Kessel C; Keizer MP; Hemke R; Nassar-Sheikh Rashid A; Dolman KM; Schonenberg-Meinema D; Ten Cate R; van den Berg JM; Maas M; Kuijpers TW
    Rheumatology (Oxford); 2020 Sep; 59(9):2392-2401. PubMed ID: 31904851
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.